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Angiogenesis is a fundamental process in tumour growth and metastatic dissemination. Possible surrogate markers for tumour
angiogenesis are the amounts of circulating endothelial cells (CEC) in peripheral blood and the plasma concentration of vascular
endothelial growth factor (VEGF). We tested the suitability of real-time PCR for CD146, an endothelial cell-specific antigen, to
quantify CEC numbers in comparison to a flow cytometry quantification. Real-time PCR of CD146 mRNA showed high sensitivity
and linearity for the quantification of cultivated primary endothelial cells added in different amounts to blood samples. Circulating
endothelial cell numbers were quantified in peripheral blood samples of breast cancer patients and healthy controls by four-colour
flow cytometry analysis and CD146 real-time PCR, and VEGF plasma concentrations were measured by ELISA. The amounts of CEC
detected with both methods correlated significantly and CEC numbers were significantly increased in newly diagnosed breast cancer
patients compared to healthy controls. Vascular endothelial growth factor concentrations correlated significantly with CEC numbers,
but there was no significant difference in VEGF levels between breast cancer patients and healthy controls indicating that VEGF
plasma levels cannot be used as surrogate marker for tumour angiogenesis. Taken together, the quantification of CEC by CD146 real-
time PCR showed equivalent results to the flow cytometry analysis. Thus, CD146 real-time PCR may be an easy and reliable
approach to quantify CEC in peripheral blood samples and could facilitate the integration of CEC measurements in clinical studies
exploring the efficacy of antiangiogenic therapies.
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Angiogenesis is a key step in tumour progression including the
spread and growth of metastases. Most tumours start growing as
avascular nodules until they reach a steady-state level of
proliferating and apoptosing cells. The tumour stays in this
dormant phase until angiogenesis is initiated and enables further
tumour growth. This angiogenic switch starts with the detachment
of pericytes and vessel dilation. The degradation of the basement
membrane and extracellular matrix allows endothelial cells to
migrate into the perivascular space towards chemotactic angio-
genic stimuli. The endothelial cells then multiply, and finally
differentiate and adhere to each other to form a lumen, which is
accompanied by basement membrane formation and pericyte
attachment (Ruoslahti, 2002; Bergers and Benjamin, 2003).
Tumours may also use alternative ways to obtain blood supply:
Vessel co-option, the use of pre-existing vessels, was first
described in the brain, but could also take place in other tumours
(Leenders et al, 2002).
Endothelial cells may appear in the circulation by detaching
from activated or damaged vessels. An increase of circulating
endothelial cells (CEC) is described in several pathologic condi-
tions that involve vascular injury or instability as myocardial
infarction, infectious vasculitis and cancer (Mutin et al, 1999;
Mancuso et al, 2001; Woywodt et al, 2003; Beerepoot et al, 2004).
These CEC are mostly viable and exhibit still proliferative capacity
despite their terminal differentiation (Lin et al, 2000; Mancuso
et al, 2001; Ribatti, 2004).
Antiangiogenic therapy is a promising new form of cancer
treatment and the effectiveness of new angiogenesis inhibitors are
currently tested in many clinical studies. Surrogate markers for
angiogenesis would be useful tools to study the effectiveness of
antiangiogenesis drugs. Since it is suggested that endothelial cells
are detached from the activated vessel wall during the formation of
new vessels the number of CEC in peripheral blood could reflect
the amount of proceeding neoangiogenesis and thus could serve as
a surrogate marker for angiogenesis. Therefore methods to
quantify CEC are of great importance. Quantification of CEC by
flow cytometry is technically complex and other reliable and easy
methods to quantify CEC should be developed. One promising
approach is the application of real-time PCR to quantify
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sendothelial cell-specific mRNA in blood samples. A possible
candidate is mRNA coding for VE-cadherin as shown by Rabascio
et al (2004). Another possible candidate for such a real-time
approach is the mRNA coding for CD146.
CD146 (also referred to as MUC18, MCAM, Mel-CAM, S-Endo-1,
P1H12 antigen) was initially identified as a marker of tumour
progression and metastasis formation in human melanoma
(Lehmann et al, 1989; Bardin et al, 1996; Shih et al, 1997).
CD146 is homologous to several cell adhesion molecules and
belongs to the immunoglobulin superfamily containing five
extracellular immunoglobulin-like domains, a single transmem-
brane domain and a short cytoplasmic domain (Sers et al, 1993).
Beside its expression in malignant melanocytes, CD146 is
constitutively expressed in all endothelial cells, irrespective of
the anatomical localisation (Bardin et al, 1996).
Several factors are involved in the control of angiogenesis. The
most potent and specific is vascular endothelial growth factor
(VEGF) (reviewed in Ferrara, 2000). Vascular endothelial growth
factor seems to play a major role in tumour neoangiogenesis:
transfection of tumour cells with VEGF results in enhanced
angiogenesis and tumour growth in animal models (Zhang et al,
1995), antibodies blocking VEGF bioactivity inhibit tumour
growth (Kim et al, 1993) and VEGF expression correlates with
the degree of tumour vascularisation and the prognosis of several
cancers (Vlaykova et al, 1999; Han et al, 2001). Therefore, VEGF
measurements in peripheral blood are often performed as
surrogate markers for angiogenesis (Tamura et al, 2001; Shima-
nuki et al, 2005).
In this study, we searched for a reliable surrogate marker
for tumour angiogenesis: We tested the sensitivity of flow
cytometry and real-time PCR to quantify endothelial cells in
blood samples and compared the amounts of CEC in peri-
pheral blood of breast cancer patients and healthy volunteers
detected with both methods. Further we analysed VEGF plasma
levels in these samples and correlated these values with the CEC
numbers.
MATERIALS AND METHODS
Cell culture
Human microvascular lung endothelial cells (HMVEC-L) were
purchased from Clonetics (Cambrex Bio Science, Walkersville,
MD, USA) and maintained in 75cm
2 flasks (Integra Biosciences,
Fernwald, Germany) with endothelial basal medium (EBM-2,
Clonetics) supplemented with EGM-2 SingleQuots (Clonetics)
containing fetal bovine serum, human VEGF, human FGF-B,
human EGF, human R3-IGF-1, ascorbic acid, heparin, hydro-
cortisone and gentamycin/amphotericin-B. Cells were subcultured
when they reached 70–90% confluence and were splitted 1:2,
usually twice a week. Cells were only used until passage 15 as
recommended by Clonetics.
Patients and sample collection
This study was approved by the regional ethic board of St Gallen,
Switzerland, and all patients and controls gave written informed
consent before study entry. For the comparison of CEC numbers
measured by flow cytometry or real-time PCR 50 blood samples
(25 samples from healthy females, five samples from healthy males,
18 samples from female breast cancer patients (newly diagnosed or
under treatment), two female patients with fibroadenoma) were
analysed. For the comparison of breast cancer patients and healthy
controls the 10 newly diagnosed female breast cancer patients and
11 healthy females with similar age were selected from the 50
samples analysed in this study. These patients were classified to the
following pTNM staging groups: one patient stage 0, four patients
stage I, two patients stage II and three patients stage III. Peripheral
blood was collected with EDTA vacutainers (BD Biosciences,
Allschwil, Switzerland).
Flow cytometry
For measurement of CEC, a method from Mancuso et al (2001) was
adapted. Mature CEC were defined as negative for haematopoietic
marker CD45 and positive for endothelial markers CD146, CD31
and CD34. For the flow cytometric analysis 100ml EDTA blood was
stained with 5ml anti-CD31-FITC (clone WM59, Serotec, Oxford,
UK), 1ml P1H12-PE (clone P1H12, Chemicon, Dietikon, Switzer-
land), 5ml anti-CD45-PerCP (clone 2D1, BD Biosciences, Allschwil,
Switzerland) and 5ml anti-CD34-APC (clone 8G12, BD Bio-
sciences). For quantification of the CEC a known amount of 6mm
latex microspheres (Polyscienes, Eppelheim, Germany) was added
to the blood as an internal standard. After incubation for 30min at
room temperature, 1ml BD Lysing Solution (BD Biosciences) was
added to lyse erythrocytes and fixate cells. After 10min, cells were
washed twice with 1ml PBS and measured in a FACS LSR flow
cytometer (BD Biosciences) using Cell Quest software (BD
Biosciences). In each blood sample 300000 events were counted.
To test the sensitivity and linearity of flow cytometric detection
of CEC, HMVEC-L were detached from the cell culture flask with
0.025% Trypsin/0.01% EDTA for 1min. After washing in PBS/10%
FCS cells were stained with P1H12-PE for 30min at room
temperature. Then the cells were washed twice with PBS, counted
and added in different amounts to the EDTA blood samples. To the
blood samples the latex microspheres were added and then blood
was lysed and washed as described above. Since the cultured
endothelial cells were stained before the addition to whole blood,
staining with P1H12-PE was sufficient to identify these cells,
whereas for the identification of CEC a complex four colour is
necessary, since some cell populations in blood are positive for
single endothelial markers.
RNA isolation
In all, 0.5ml EDTA blood was mixed with 14ml of erythrocyte
lysis buffer (0.899% (w/v) ammonium chloride, 0.1% (w/v)
potassium bicarbonate, and 0.0037% (w/v) EDTA, pH 7.3) and
incubated for 10min at room temperature. After 10min centri-
fugation with 500g the buffer was removed and the cell pellet was
resuspended in 350ml RLT buffer (Qiagen, Basel, Switzerland) and
stored at  201C until RNA isolation. RNA was isolated with the
RNeasy Kit plus additional Dnase digestion (Qiagen) according to
the manufacturer’s instructions. RNA was eluted in 50ml RNase-
free water. The quality of the isolated RNA was checked by gel
electrophoresis.
Reverse transcription
Samples for real-time PCR were reverse transcribed with the
Taqman Reverse Transcription Kit from Applied Biosystems,
Rotkreuz, Switzerland, according to the manufacturer’s protocol.
Samples were reverse transcribed with random hexamer primers
and the maximal allowed volume of RNA sample that can be added
to the reverse transcription reaction was used. To verify that the
primers do not amplify genomic DNA, some RNA samples were
diluted and incubated as the normal samples, but did not receive
reverse transcriptase (RT samples).
Primers
PCR primers for CD146 (NCBI reference sequence M28882) were
designed with Primer Express software (Applied Biosystems) and
were placed in two different exons (exons 2 and 6) to eliminate
amplification of genomic DNA. The following primers for CD146
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swere used: forward primer 50-cca agg caa cct cag cca tgt c-30 and
reverse primer 50-ctc gac tcc aca gtc tgg gac gac t-30. The resulting
amplicon had a size of 437bp.
Real-time polymerase chain reaction
For the amplification of CD146 1ml cDNA was added to QuantiTect
SYBR Green PCR Master Mix (Qiagen) containing 400nM forward
as well as reverse primers. PCR was performed in a Taqman 7700
(Applied Biosystems) using the following thermal settings: one
cycle of 15min at 951C, and 40 cycles of 15s at 941C, 30s at 601C
and 30s at 721C.
Relative mRNA expression was calculated with the DDCt-
method. As calibrator the sample with the lowest Ct-value was
used and set to 100%.
To test the sensitivity and linearity of PCR detection of CEC,
HMVEC-L were detached from the cell culture flask with 0.025%
Trypsin/0.01% EDTA for 1min. After washing in PBS/10% FCS
cells were counted and added in different amounts to 0.5ml EDTA
blood and RNA was isolated as described above.
ELISA measurement
Plasma was prepared from EDTA blood samples by centrifugation
for 10min at 14000g. Plasma levels of VEGF were quantified by
sandwich ELISA using the DuoSet ELISA Kit from R&D Systems
(Wiesbaden, Germany) according to the manufacturer’s instruc-
tions. Vascular endothelial growth factor measurements were
performed in plasma and not in serum samples, since VEGF is
released from activated platelets during the coagulation process
(Hormbrey et al, 2002).
Statistical analysis
Statistical analysis was performed using the GraphPad Instat
software (Instant Statistics, GraphPad Software, San Diego, USA).
For all data, unpaired nonparametric testing was performed with
the Mann–Whitney test. Correlation testing was carried out with
the Pearson’s correlation analysis.
RESULTS
Sensitivity and linearity of CEC detection by real-time PCR
The standard method to detect CEC is multicolour flow cytometry.
To compare the flow cytometric detection of endothelial cells with
real-time PCR, we added different amounts of cultured human
endothelial cells (HMVEC-L) to blood and analysed this by flow
cytometry and real-time PCR for CD146. With the flow cytometric
approach 0.5 added endothelial cellsml
 1 blood could be detected
and the amounts of added endothelial cells correlated highly
(r¼0.9981, Po0.001) with the amounts of endothelial cells
retrieved by flow cytometric analysis (Figure 1A).
For the quantification of endothelial cells by real-time PCR, we
measured the amounts of CD146 mRNA. This PCR approach
showed a very high sensitivity, even the lowest amount of 0.6
HMVEC-Lml
 1 blood (Ct-value: 31.5) was clearly different from the
control blood sample without added HMVEC-L (Ct-value: 35.3).
The relative expression of CD146 in real-time PCR correlated
highly (r¼0.996, Po0.001) with the added amounts of HMVEC-L
(Figure 1B). This comparison showed that the quantification of
CD146 mRNA could be used to quantify endothelial cells in blood
samples, even in the range of very low CEC amounts. The
sensitivity and linearity of the PCR method was comparable to the
flow cytometric analysis.
Correlation of CEC amounts detected by flow cytometry
and real-time PCR
In blood samples of healthy controls and patients CEC were
quantified in parallel by flow cytometry and CD146 real-time PCR.
The amounts of CEC detected in 50 blood samples with both
methods correlated significantly (r¼0.6744, Po0.001) (Figure 2).
Correlation of CEC amounts with plasma levels of VEGF
Since VEGF is one of the major cytokines triggering angiogenesis
we also measured plasma levels of this cytokine in the blood
samples of healthy controls and patients and correlated the plasma
concentrations with the amounts of CEC detected by flow
cytometry. Plasma levels of VEGF correlated significantly
(r¼0.4222, P¼0.0025) with the amounts of CEC detected by flow
cytometry (Figure 3).
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Figure 1 Sensitivity and linearity of the detection of endothelial cells in
blood samples by flow cytometry and CD146 real-time PCR. Cultured
human endothelial cells (HMVEC-L) were added in different amounts to
blood and then the amounts of endothelial cells were determined with (A)
four-colour flow cytometry analysis and (B) CD146 real-time PCR.
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sComparison of CEC amounts and VEGF plasma levels in
breast cancer patients and healthy controls
The amounts of CEC in peripheral blood of breast cancer patients
and healthy controls were quantified by flow cytometry and real-
time PCR of CD146. With flow cytometry 1.0 CECml
 1 blood
(median) were detected in the blood samples of the healthy controls,
whereas in the breast cancer patients at the time of diagnosis 3.3
CECml
 1 blood (median) were found (Figure 4A). This difference
between patients and controls was significant (P¼0.0021).
With real-time PCR the relative amounts of CEC were
determined by quantification of CD146 mRNA in the blood
samples. The relative amount of CEC in the control population was
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Figure 2 Correlation of CEC amounts detected by flow cytometry and
CD146 real-time PCR. The amounts of CEC were quantified in 50
peripheral blood samples of patients and healthy controls by four-colour
flow cytometry analysis and CD146 real-time PCR.
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Figure 3 Correlation of CEC amounts and VEGF plasma levels. The
concentrations of VEGF were quantified in 50 plasma samples of patients
and healthy controls by ELISA and correlated with the amounts of CEC
detected in these blood samples by four-colour flow cytometry analysis.
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Figure 4 Comparison of CEC amounts and VEGF plasma levels in breast
cancer patients and healthy controls. The amounts of CEC in peripheral
blood samples of 11 healthy controls and 10 newly diagnosed breast cancer
patients were determined by (A) four-colour flow cytometry analysis and
(B) CD146 real-time PCR. (C) Concentrations of VEGF in the plasma
samples of these patients and controls were quantified by ELISA **Po0.01,
***Po0.001 vs values of healthy controls.
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s0.47 (median), whereas the breast cancer patients had a relative
CEC amount of 5.9 (median) (Figure 4B). This difference was also
significant (P¼0.0004).
VEGF was measured by sandwich ELISA in plasma of breast
cancer patients and healthy controls. In healthy controls VEGF
plasma levels were 37.4pgml
 1 (median), in the breast cancer
patients concentrations of 49.6pgml
 1 (median) were reached
(Figure 4C). This difference between healthy controls and patients
was not significant.
DISCUSSION
VEGF was originally identified for its ability to induce vascular
permeability and to stimulate endothelial cell growth. Now it is
recognised as a key factor required for tumour neoangiogenesis
(Ferrara and Gerber, 2001). Currently, several inhibitors of the
VEGF-signaling pathway have entered clinical trials to test their
efficacy as antiangiogenic drugs (reviewed in Verheul and Pinedo,
2003). Unfortunately, clinical markers to assess neoangiogenesis in
patients or the response to antiangiogenic treatment are still
scanty. Circulating endothelial cell numbers in peripheral blood
seem to be a relevant marker of neoangiogenesis since CEC are
elevated in cancer patients and the amounts of CEC correlates with
progressive disease (Mancuso et al, 2001; Beerepoot et al, 2004).
The amounts of CEC in peripheral blood can be measured by flow
cytometry, but this requires fresh blood samples and a complex
four-colour analysis with the acquisition of many events. Another
limitation of this method is the danger to falsely identify platelet
aggregates as endothelial cells. We observed in some patient
samples (three in 115) high numbers of events that were highly
positive for the endothelial cell marker CD146, but a closer analysis
of these events by staining the blood with the DNA dye Hoechst
33342 and flow cytometric analysis with UV laser showed that
these events did not contain DNA and thus could not be
endothelial cells. Since CD146 is found in a soluble form in
human plasma (Bardin et al, 2003) these CD146-positive events
could result from platelet aggregates which have bound soluble
CD146 resulting in specific staining of these complexes with the
anti-CD146 antibody.
Real-time PCR offers several advantages compared to flow
cytometry. It is possible to freeze the blood samples facilitating the
integration of such measurement in clinical routine work and the
standardisation of the real-time PCR method is easier than a
standardisation of the complex four-colour flow cytometry
analysis. Further in flow cytometry there is always the danger of
unspecific staining with antibodies, especially in patients with
activated leucocytes, and the detection of platelet aggregates as
cells. This could in particular influence the detection of such tiny
populations as the CEC.
To overcome these limitations we searched for another method
to quantify CEC in peripheral blood. We therefore tested real-time
PCR for the endothelial cell marker CD146 to quantify CEC in
blood samples. Since the flow cytometric measurement of CD146
showed a stable expression of CD146 on CEC, we assumed that the
quantification of CD146 mRNA would allow to determine the
amounts of CEC present in the blood samples. We therefore
compared the sensitivity and linearity of flow cytometry and real-
time PCR detection of endothelial cells. Cultivated primary
endothelial cells added to blood samples were detected with both
methods with a similar sensitivity and a strong linearity with
increasing numbers of endothelial cells. Even low amounts of
endothelial cells (below 1cellml
 1 blood) could be detected with
both methods.
Next, we compared the amounts of CEC in peripheral blood of
breast cancer patients and healthy controls quantified by flow
cytometry and real-time PCR. This comparison showed a strong
correlation between both methods.
In concordance to literature our comparison of controls
and newly diagnosed breast cancer patients showed increased
numbers of CEC in the cancer patients with both methods
(Mancuso et al, 2001; Beerepoot et al, 2004). In real-time PCR the
difference was more pronounced as in the flow cytometric
detection. This could result from the difference in detection of
dead cells with both methods: With flow cytometry also dead cells
that still display intact morphology could be measured, but the
mRNA in such cells is probably lost and therefore the real-time
PCR will not detect these dead cells. This is supported by the
previous finding that the amounts of VE-cadherin mRNA is
strongly reduced in apoptotic endothelial cells compared to viable
cells (Rabascio et al, 2004).
In the real-time approach we did not normalise to any
housekeeping gene. For other real-time PCR analyses it is
useful to normalise for housekeeping genes as b-actin or GAPDH
to eliminate differences in cell numbers, RNA preparation
and cDNA synthesis. However, for the quantification of CEC
it is not useful to apply such a normalisation strategy. The
normalisation to a housekeeping gene would result in the
calculation of a ratio of CEC to leucocytes, since the housekeeping
genes are expressed in all cells and the leucocytes are at least in
a 1000-fold surplus compared to the CEC. Such a ratio would
not reflect absolute CEC numbers in the blood samples, since
the ratio also depends on the number of leucocytes which could
be strongly influenced by infections or cancer therapies as chemo-
therapy or radiation. To get information about the real amounts
of CEC in peripheral blood it would be necessary to take the
leucocyte counts of the blood samples into account. To test the
variations in our method, RNA was prepared several times
individually from the same blood sample and with these separate
samples real-time PCR analysis was performed. Since the
variations between these samples were minimal (s.d. of Ct-values:
0.28) a normalisation to a housekeeping gene and inclusion of the
leucocyte numbers is not necessary in this analysis and would only
result in increased inaccuracy instead of reduced variation.
Nevertheless we recommend to include the measurement of a
housekeeping gene as an internal control for individual RNA/
cDNA quality.
The plasma levels of VEGF are often used as surrogate marker
for angiogenesis. We therefore compared VEGF plasma concen-
trations with the amounts of CEC detected by flow cytometry and
CD146 real-time PCR. We found a correlation between VEGF
plasma levels and the CEC numbers. The comparison of VEGF
levels in breast cancer patients and healthy controls did not show a
significant difference as it was demonstrated for the CEC amounts.
Also very high amounts of VEGF were found in two healthy
controls. These observations could result from limitations of the
ELISA measurement where factors as crossreacting antibodies or
lipemic or haemolytic samples could falsify VEGF measurement.
Thus, VEGF seems not to be an ideal surrogate marker for
angiogenesis.
In conclusion, we could show that the quantification of CEC by
real-time PCR for the endothelial cell marker CD146 is equivalent
to four-colour flow cytometry analysis. Thus, CD146 real-time PCR
is an easy and reliable alternative to quantify CEC in peripheral
blood samples. This may considerably facilitate the determination
of the angiogenic status of patients and the evaluation of
antiangiogenic therapeutics.
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